Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer

Lung Cancer is a fatal disease with the highest worldwide morbidity and mortality rates. Despite recent advances in targeted therapy and immune checkpoint inhibitors for Cancer, their efficacy remained limited. Therefore, we designed a Newcastle disease virus (NDV)-modified tumor whole-cell vaccine as a therapeutic vaccine and identified its antigen presentation level to develop effective immunotherapy. Then, we calculated the therapeutic and immune-stimulating effects of NDV modified lung Cancer cell vaccine and intratumoral NDV injection combination on tumor-bearing mice. The results showed that the immunogenic cell death (ICD) expression in NDV modified lung Cancer cell vaccine stimulates dendritic cell maturation and T cell activation in vivo and in vitro. Moreover, NDV modified lung Cancer cell vaccine combined with intratumoral NDV injection could significantly inhibit tumor growth and enhance the differentiation of Th1 cells and Inflammatory cell infiltration in vivo, leading to an excellent immunotherapeutic effect. Therefore, our results revealed that NDV modified lung Cancer cell vaccine combined with intratumoral NDV injection could promote antigen presentation and induce a strong anti-tumor immune response, which provided a promising combined therapy strategy for tumor immunotherapy. This article is protected by copyright. All rights reserved.

Immunotherapy of lung cancer; Newcastle disease virus; T cell response; Tumor cell vaccine; immunogenic cell death.